Effect of cimetidine and phenobarbital on metabolite kinetics of omeprazole in rats

Archives of Pharmacal Research

Volumn 28, Issue 10, 2005, Pages 1196-1202

  Park, Eun Ja ^a   Cho, Hea Young ^b   Lee, Yong Bok ^a  

^a Chonnam National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Cimetidine; Interaction; Omeprazole; Pharmacokinetics; Phenobarbital

Indexed keywords

EID: 27744493447     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02972986     Document Type: Article

References (25)

1. Andersson, T., Miners, J. O., Veronese, M. E., and Birkett, D. J., Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol., 37, 597-604 (1994).
2. Andersson, T., Miners, J. O., Veronese, M. E., Tassaneeyakul, W., Meyer, U. A., and Birkett, D. J., Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol., 36, 521-530 (1993).
3. Badyal, D. K. and Dadhich, A. P., Cytochrome p450 and drug interactions. Indian J. Pharmacol., 33, 248-259 (2001).
4. Black, J. W., Histamine H2-receptor antagonists and gastric acid secretion - A progress report. Klin. Wochenschr., 54, 911-914 (1976).
5. Branch, R. A., Shand, D. G., Wilkinson, G. R., and Nies, A. S., Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey; Relative contributions of enzyme induction and increased hepatic blood flow. J. Clin. Invest., 53, 1101 (1974).
6. Carlile, D. J., Zomorodi, K., and Houston, J. B., Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver studies with induced livers involving diazepam. Drug Metab. Dispos., 25, 903-911 (1997).
7. Cheng, F. C., Ho, Y. F., Hung, L. C., Chen, C. F., and Tsai, T.H., Determination and pharmacokinetic profile of omeprazole in rat blood, brain and bile by microdialysis and highperformance liquid chromatography. J. Chromatogr. A, 949, 35-42 (2002).
8. Gabrielsson, J. and Weiner, D., Pharmacokinetic and pharmacodynamic data analysis: concepts & applications 3rd edition, Apotekarsocieteten, Stockholm, (2000).
9. Howden, C. W., Clinical pharmacology of omeprazole, Clin. Pharmacokinet., 20, 38-49 (1991).
10. Kakizaki, S., Yamamoto, Y., Ueda, K., Moore, R., Sueyoshi, T., and Negishi, M., Phenobarbital induction of drug/steroidmetabolizing enzymes and nuclear receptor CAR. Biochim. Biophy. Acta, 1619, 239-242 (2003).
11. 2-receptor. Gastroenterology, 82, 84-88 (1982).
12. 18 column. J. Chromatogr., 579, 299-305 (1992).
13. Levy, R. H., Hachad, H., Yao, C., and Ragueneau-Majlessi, I., Relationship between extent of inhibition and inhibitor dose, literature evaluation based on the metabolism and transport drug interaction database. Curr. Drug Metab., 4, 371-380 (2003).
14. Marc, N., Galisteo, M., Lagadic-Gossmann, D., Fautrel, A., Joannard, F., Guillouzo, A., and Corcos, L., Regulation of phenobarbital induction of the cytochrome P450 2b9/10 genes in primary mouse hepatocyte culture. Eur. J. Biochem., 267, 963-970 (2000).
15. Mino, K., Watanabe, J., and Kanamura, S., Effect of 3-methylcholanthrene administration on expression of cytochrome P-450 isoforms induced by phenobarbital in rat hepatocytes. J. Histochem. Cytochem., 46, 1151-1160 (1998).
16. Petersen, K. U., Omeprazole and the cytochrome P450 system. Aliment. Pharmacol. Ther., 9, 1-9 (1994).
17. Regardh, C. G., Gabrielsson, M., Hoffman, K. J., Lofberg, I., and Skanberg, I., Pharmacokinetics and metabolism of omeprazole in animals and man. Scan. J. Gastroenterol. Suppl., 108, 79-94 (1985).
18. Shiga, T., Hashiguchi, M., Urae, A., Kasanuki, H., and Rikihisa, T., Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin. Pharmacol. Ther., 67, 222-228 (2000).
19. Sudjana-Sugiaman, E., Eggertsen, G., and Bjorkhem, I., Stimulation of HMG-CoA reductase as a consequence of phenobarbital-induced primary stimulation of cholesterol 7 alpha-hydroxylase in rat liver. J. Lipid Res., 35, 319-327 (1994).
20. Szutowski, M.M., Zalewska, K., Jadczak, M., and Marek, M., In vivo effect of diallyl sulfide and cimetidine on phenacetin metabolism and bioavailability in rat. Acta Biochim. Pol., 49, 249-256 (2002).
21. Waxman, D. J. and Walsh, C., Phenobarbital-induced rat liver cytochrome P-450. Purification and characterization of two closely related isozymic forms. J. Bio. Chem., 257, 10446-10454 (1982).
22. Wilde, M. I. and McTavish, D., Omeprazole: An update of its pharmacology and therapeutic use in acid-related disorders. Drugs, 48, 91-131 (1994).
23. WinNonlin™ User's Guide Ver. 3.0, Pharsight Corp., Mountain View, CA, U.S.A. (1999).
24. Wintrobe, M. M., Lee, G. R., and Boggs, D. R., Clinical Hematology 7th ed. Lea & Febiger, Philadelphia (1974).
25. Yamano, K., Yamamoto, K., Katashima, M., Kotaki, H., Takedomi, S., Matsuo, H., Ohtani, H., Sawada, Y., and Iga, T., Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data. Drug Metab. Dispos., 29, 443-452 (2001).